Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 161

Sort by

Sort Order Select

Journal Articles

Influence of TP53 gene mutations and their allelic status in myelodysplastic syndromes with isolated 5q deletion

Blood (2024) 144 (16): 1722–1731.

https://doi.org/10.1182/blood.2024023840

Published: 2024

Includes: Supplemental data

Journal Articles

Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma

Blood (2024) 144 (3): 334–338.

https://doi.org/10.1182/blood.2024024526

Published: 2024

Includes: Supplemental data

Journal Articles

Patients with Chronic Lymphocytic Leukemia Carrying t(14;19) Display a Distinctive Transcriptomic Profile and Adverse Outcome, Which Might be Overcome Continuous Therapy with BTK Inhibitors. an Italian Campus CLL and Eric Study

Andrea Visentin, Enrico Gaffo, Moritz Furstenau, Jennifer A. Woyach, Panagiotis Baliakas, Kerry A Rogers, Cecelia Miller, Claudia Haferlach, Karla Plevova, David Graham Oscier, Zadie Davis, Florence Nguyen Khac, Eleonora Roncaglia, Gian Matteo Rigolin, Anastasia Athanasiadou, Fanny Baran-Marszak, Alberto Valiente, Maria Jose Terol, Pau Abrisqueta, Blanca Espinet, Anna Puiggros, Annalisa Martines, Laura Bonaldi, Francesca Romana Mauro, Lydia Scarfo, Thomas Chatzikonstantinou, Eugen Tausch, Karl Anton Kreuzer, Arnon P. Kater, Francesc Bosch, Michael Doubek, Panayiotis Panayiotidis, Olga Kalashnikova, Federica Frezzato, Monica Facco, Valeria Ruocco, Alessia Buratin, Silvia Orsi, Alessandro Cellini, Francesco Angotzi, Chiara Adele Cavarretta, Ivan Zatta, Andrea Serafin, Robin Foa, Barbara F. Eichhorst, Antonio Cuneo, Kostas Stamatopoulos, Paolo Ghia, Stefania Bortoluzzi, Livio Trentin

Blood (2023) 142 (Supplement 1): 3275.

https://doi.org/10.1182/blood-2023-174569

Published: 2023

Journal Articles

The Post-CAR Prognostic Index (PC-PI): A New Prognostic Score to Predict Overall Survival in Large B-Cell Lymphoma Patients Progressing after Chimeric Antigen Receptor T-Cell Therapy

Blood (2023) 142 (Supplement 1): 227.

https://doi.org/10.1182/blood-2023-184942

Published: 2023

Journal Articles

Beyond MIPI: Harnessing Machine Learning and Histological Subtype for Enhanced MCL Prognostication of Survival

Blood (2023) 142 (Supplement 1): 4419.

https://doi.org/10.1182/blood-2023-179174

Published: 2023

Journal Articles

Englumafusp Alfa (CD19-4-1BBL) and Glofitamab Combination in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL): Biomarker Results from a Phase I Dose-Escalation Trial

Blood (2023) 142 (Supplement 1): 3017.

https://doi.org/10.1182/blood-2023-173677

Published: 2023

Journal Articles

Apixaban Vs Vitamin K Antagonist As Anticoagulant Therapy in Patients with End-Stage Kidney Disease on Hemodialysis and with Atrial Fibrillation

Sofia Muzio, Gonzalo Artaza, Olga Benitez Hidalgo, Vicente Cortina, Desiree Campoy, Francisco Beas, Marc Bosch, Marina Serra, Francesc Bosch, Pável E Olivera

Blood (2023) 142 (Supplement 1): 4019.

https://doi.org/10.1182/blood-2023-190604

Published: 2023

Journal Articles

Response to Mosunetuzumab in Patients with B-Cell Lymphomas Relapsed or Refractory after CAR-T Cell Therapy Is Associated with Changes in Lymphocyte Counts

Elise A. Chong, Elicia Penuel, Nancy L. Bartlett, Francesc Bosch, L. Elizabeth Budde, Keith Fay, Ian W. Flinn, Andre Goy, Anita Kumar, Rachel Lundberg, Ellen B. Napier, Loretta J. Nastoupil, Mazyar Shadman, Michael C. Wei, Mei Wu, Shen Yin, Emeline R. Chong, Stephen J. Schuster

Blood (2023) 142 (Supplement 1): 1752.

https://doi.org/10.1182/blood-2023-190201

Published: 2023

Journal Articles

TP53 G ene a llelic State in Myelodysplastic Syndromes (MDS) with Isolated 5q Deletion

Blood (2023) 142 (Supplement 1): 1001.

https://doi.org/10.1182/blood-2023-179171

Published: 2023

Journal Articles

Multi-Omics Exploration of Adaptive Mechanism to BTK Inhibition By Ibrutinib in CLL Identified TMBIM6/BI-1 As a Poor Prognosis Variable and Potential Therapeutic Target

Daniel Medina, Laura Palomo, Víctor Navarro, Oriol Castells, Belén Sánchez, Pau Marc Muñoz Torres, Carlota Pagès Geli, Cristina Hernández, Gemma Pujadas, Alba Cabirta Touzón, Christelle Ferrà, Miguel Alcoceba, María José Terol, Rafael Andreu, Francesc Bosch, Pau Abrisqueta, Marta Crespo

Blood (2023) 142 (Supplement 1): 3254.

https://doi.org/10.1182/blood-2023-185683

Published: 2023

Journal Articles

Macrophages Play a Key Role in Controlling Tumor Growth and Response to Immunotherapy in Primary Central Nervous System Lymphoma

Carlota Pages-Geli, Daniel Medina, Cristina Hernandez, Patricia Fernandez, Gemma Pujadas, Francesc Bosch, Marta Crespo

Blood (2023) 142 (Supplement 1): 1642.

https://doi.org/10.1182/blood-2023-180719

Published: 2023

Journal Articles

Clinical Impact of the New Bone Marrow Blasts Cutoff Defined By the International Classification Consortium (ICC) in Myeloid Neoplasms with Mutated TP53 gene

Blood (2023) 142 (Supplement 1): 3235.

https://doi.org/10.1182/blood-2023-181698

Published: 2023

Journal Articles

Impact of Prior Bendamustine Exposure on Bispecific Antibody Treatment Outcomes for Patients with B-Cell Lymphoma

Gloria Iacoboni, Angel Serna, Victor Navarro Garces, Ana Jimenez Ubieto, Evelyn Valencia, Alberto Lopez Garcia, Itziar Carro, Sergi Camarillas, Josu Iraola, Lucia Medina, Gala Vega, Maria Pozas, Anna Maria Sureda Balari, Raul Cordoba, Miguel Canales, Francesc Bosch, Pere Barba, Pau Abrisqueta Costa

Blood (2023) 142 (Supplement 1): 310.

https://doi.org/10.1182/blood-2023-184883

Published: 2023

Journal Articles

Novel Agents May be Preferable to Standard Chemotherapy in Second-Line for Early Relapsing Follicular Lymphoma (FL) Patients

Blood (2023) 142 (Supplement 1): 6168.

https://doi.org/10.1182/blood-2023-186019

Published: 2023

Journal Articles

Resistance Mechanisms Impacting Bispecific Antibody (BsAbs) and Chimeric Antigen Receptor (CAR) T-Cell Therapy Outcomes in Large B Cell Lymphoma (LBCL) Patients

Blood (2023) 142 (Supplement 1): 1635.

https://doi.org/10.1182/blood-2023-186072

Published: 2023

Journal Articles

Deciphering Transcriptomic and (Epi)Genetic Signatures of Central Nervous System Infiltration in Patients Diagnosed with Diffuse Large B-Cell Lymphoma

Carlota Pages-Geli, Sabela Bobillo, Pau Abrisqueta, Josep Castellvi, Laura Palomo, Damiana Alvarez, Manel Esteller, Francesc Bosch, Marta Crespo

Blood (2023) 142 (Supplement 1): 1618.

https://doi.org/10.1182/blood-2023-174653

Published: 2023

Journal Articles

Early-Onset Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) without SF3B1 Mutations in Adults: Enrichment with Germline Variants in Genes Responsible for Congenital Sideroblastic Anemias

Sandra Novoa Jáuregui, Tzu Chen, Sara Torres-Esquius, Salvador Carrillo-Tornel, Marta Santiago, Teresa Bernal Del Castillo, Francisca Maria Hernandez, Alessandro Liquori, Ivan Martin Castillo, Mar Tormo, Barbara Tazon, Adoracion Blanco, Laura Palomo, Jose Cervera, Francesc Bosch, David Valcarcel, Maria Diez-Campelo, Julia Montoro, Andres Jerez

Blood (2023) 142 (Supplement 1): 4610.

https://doi.org/10.1182/blood-2023-185836

Published: 2023

Journal Articles

Glofitamab Plus R-CHOP Induces High Response Rates with a Manageable Safety Profile in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A 12-Month Analysis from a Phase Ib Study

Blood (2023) 142 (Supplement 1): 3085.

https://doi.org/10.1182/blood-2023-174081

Published: 2023

Journal Articles

Glofitamab Plus Polatuzumab Vedotin Continues to Demonstrate Frequent and Durable Responses and Has a Manageable Safety Profile in Patients with ≥2L Relapsed/Refractory DLBCL, Including HGBCL, and in Patients with Prior CAR T-Cell Therapy: Updated Results from a Phase Ib/II Study

Blood (2023) 142 (Supplement 1): 4460.

https://doi.org/10.1182/blood-2023-174213

Published: 2023

Journal Articles

Incidence, Risk Factors and Clinical Impact of Sars-Cov-2 Prolonged Viral Shedding in Patients Diagnosed with Hematologic Malignancies

Blood (2023) 142 (Supplement 1): 3927.

https://doi.org/10.1182/blood-2023-191146

Published: 2023

NARROW

Influence of TP53 gene mutations and their allelic status in myelodysplastic syndromes with isolated 5q deletion

Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma

Patients with Chronic Lymphocytic Leukemia Carrying t(14;19) Display a Distinctive Transcriptomic Profile and Adverse Outcome, Which Might be Overcome Continuous Therapy with BTK Inhibitors. an Italian Campus CLL and Eric Study

The Post-CAR Prognostic Index (PC-PI): A New Prognostic Score to Predict Overall Survival in Large B-Cell Lymphoma Patients Progressing after Chimeric Antigen Receptor T-Cell Therapy

Beyond MIPI: Harnessing Machine Learning and Histological Subtype for Enhanced MCL Prognostication of Survival

Englumafusp Alfa (CD19-4-1BBL) and Glofitamab Combination in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL): Biomarker Results from a Phase I Dose-Escalation Trial

Apixaban Vs Vitamin K Antagonist As Anticoagulant Therapy in Patients with End-Stage Kidney Disease on Hemodialysis and with Atrial Fibrillation

Response to Mosunetuzumab in Patients with B-Cell Lymphomas Relapsed or Refractory after CAR-T Cell Therapy Is Associated with Changes in Lymphocyte Counts

TP53 G ene a llelic State in Myelodysplastic Syndromes (MDS) with Isolated 5q Deletion

Multi-Omics Exploration of Adaptive Mechanism to BTK Inhibition By Ibrutinib in CLL Identified TMBIM6/BI-1 As a Poor Prognosis Variable and Potential Therapeutic Target

Macrophages Play a Key Role in Controlling Tumor Growth and Response to Immunotherapy in Primary Central Nervous System Lymphoma

Clinical Impact of the New Bone Marrow Blasts Cutoff Defined By the International Classification Consortium (ICC) in Myeloid Neoplasms with Mutated TP53 gene

Impact of Prior Bendamustine Exposure on Bispecific Antibody Treatment Outcomes for Patients with B-Cell Lymphoma

Novel Agents May be Preferable to Standard Chemotherapy in Second-Line for Early Relapsing Follicular Lymphoma (FL) Patients

Resistance Mechanisms Impacting Bispecific Antibody (BsAbs) and Chimeric Antigen Receptor (CAR) T-Cell Therapy Outcomes in Large B Cell Lymphoma (LBCL) Patients

Deciphering Transcriptomic and (Epi)Genetic Signatures of Central Nervous System Infiltration in Patients Diagnosed with Diffuse Large B-Cell Lymphoma

Early-Onset Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) without SF3B1 Mutations in Adults: Enrichment with Germline Variants in Genes Responsible for Congenital Sideroblastic Anemias

Glofitamab Plus R-CHOP Induces High Response Rates with a Manageable Safety Profile in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A 12-Month Analysis from a Phase Ib Study

Glofitamab Plus Polatuzumab Vedotin Continues to Demonstrate Frequent and Durable Responses and Has a Manageable Safety Profile in Patients with ≥2L Relapsed/Refractory DLBCL, Including HGBCL, and in Patients with Prior CAR T-Cell Therapy: Updated Results from a Phase Ib/II Study

Incidence, Risk Factors and Clinical Impact of Sars-Cov-2 Prolonged Viral Shedding in Patients Diagnosed with Hematologic Malignancies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only